Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02675946
Title CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Curegenix Inc.
Indications

pancreatic adenocarcinoma

Advanced Solid Tumor

colorectal adenocarcinoma

hepatocellular carcinoma

bile duct carcinoma

gastric adenocarcinoma

esophageal carcinoma

Therapies

CGX1321

CGX1321 + Pembrolizumab

Cetuximab + CGX1321 + Encorafenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST